Member Info for Nolupus

I believe that the company would be better served by being up front with their shareholders and not try to embolish reality...it's sometimes better to call a spade a spade , in my view .

As for the " strong buy " crowd , they are notably absent from the board since last week ( surprise surprise )

Reality will take a while to sink in , imo

IMM is a tiny company , with no income outside tax credits who Rely on it's shareholders to supply the cash necessary to continue to exist and to invest in their pipeline with the hope that the pipeline will ( at some stage) generate enough income to be able to reward shareholders through dividends.

Biotech take a long time to achieve that maturity and many/ most fail to ever get to that stage .

My Outlook is this..

After cutting costs to the bare minimum ( except maybe some big salaries ) IMM have a very small employee base + some outside contract workers. They have rented office spaces and a rented lab in Bordeaux ( and a few P.O. adresses).

They have very few assets outside of their patents and pipeline, imo

They are and have been reliant on Landstead for many years now to fund the company (as most of the private funding has dried up )

Their HOPE, is that partnerships will be signed to deliver cash for clinical trials but until that happens, they are unable to move forward ( apart from some preclinical work or not too much cash consuming trials )

Let's hope that they will sign some partnerships to enable them to move forward as otherwise they will be in a catch 22 situation.

This is just my perspective /opinion and everyone to their own

Our perception of the reality and reality itself are two different concepts 🧐

If one is being objective, Not much has changed since Yesterday, except perception and sentiment 🧐

The company is the same , it's got the same management and the same pipeline ( even a new one )

The risks that are associated with the company are the same ( except for the cash runway being extended )

Only the timeframe seems to have been extended and people's perceptions have gone from " strong buy " to " strong sell " but the company has not changed just perception, imo

But

Everyone to their own convictions and " perceptions " as per usual

" And on the funding side, isn’t it fair to say that this raise isn’t really about “keeping the lights on”, but about funding a fast‑tracked product they’re pushing through the 505(b)(2) pathway in Type 1 diabetes? They’ve guided at least H2 2028 on runway now, so this looks more like a deliberate move to add value to the pipeline than a dilution for dilution’s sake or some kind of back‑handers story."

If we are to go by Wigwammer's figures , IMM burn between 2million and 2.5 million every year " to keep the lights on " so Yesterday we were told that the cash runway has been extended to Q4 2028 instead of Q4 2026 ...

That means that the 6 million " expected " from Landstead will be spent in 2 years so between 4-5 million will be used to " keep the lights on " and the rest for the new pipeline ?

Everyone to their own convictions as per usual

" If you don’t use a lot of money, you don’t need a lot of money. If you don’t need a lot of money - you don’t need to undertake massive dilutions. "

Whilst the expected cash runway has now been extended to the end of 2028 instead of the end of 2026 , it's difficult to see what actually funding will be spent on the "new pipeline " ....

Bonneville,

Whilst i understand what you are saying, I cannot agree with you on that " it's official "

Whilst this placing is a signal that no deal is imminent, it doesn't mean that no deal will be concluded

Best regards

The " strong buy " crowd are more to blâme than Tim himself , imo

Best regards to those that sold the brochure last week and the only risk they mentioned " was the risk of being on the sidelines "

Lordloadsoflolly,

I am about to ring that number now 🤓

Don't take things personally Tim , although some people are angry today as they are dissapointed that you haven't delivered the news that they were expecting...

Sentiment comes and goes on these boards and whilst you are keeping the lights on, others are counting their losses ( whilst some are showing their " class " and counting their profits )

We are all responsible for our own trades and convictions so we can only say that we were mistaken in our optimistic approach without taking into account the inherent risks of putting our hard earned capital into biotech stocks .

High risk , high rewards 🧐

As always after the dust has settled we know that we can rely on you to deliver positive news flow and shareholder value to compensate the dilution etc etc

Best regards

We can all appreciate the irony of the chosen date for this placing 🧐

The Irish kiss the blarney stone and have the gift of the gab for the rest of their lives .

Have a Jameson or two to celebrate Tim

Halfbutt,

Tim never said that they would not be doing any further placings....

He said that they had " no intention. " Of doing a placing as they " expected " funding to come from licencing deals

As always , one should note the difference ...

Scrodingercat,

I think it's not the the right moment for me to give any opinion...

Let's leave the dust settle first ...

Onetomany,

Out of common decency for many of the Pi who have lost out badly , please refrain from " gloosing "

Best regards

Halfbutt,

I agree with that statement and i hope that will happen for you, even though i think that the chances of that happening are slim tbh

Best of luck to you and the missus 😉

Oldred7

I will stand by my hypothesis, and just because it's not the opinion of others , doesn't make it false until proven to be so ...

Only time will tell...

So , are you now stating that in your opinion Upto $ 25 million is enough money to get the new p140 trialed and tested to meet all the Fda's criteria in Lupus ?

I don't believe that to be true but whatever, my hypothesis which you have conceded to , is that the costs will be much higher that what is on the table since 2019

- What that implies and what everyone incorporates into their decisions is entirely up to them ...

Best regards

Whilst some people can twist and turn and deform things all they want ....

The reasoning that the costs of bringing the new P140 programme to start and finish will be, imo substancially more than what Avion have proposed to inject ( "Upto $25 million ) still stands

Best regards

The main point was that the Upto $25 million which was signed in 2019 to redo a P3 trial in Lupus, is in my hypothesis not enough to undergo the new clinical programme.

My hypothesis is also consistant with the fact that no clinical trial has actually started despite the fact that the CRO was appointed in 2023 .

We can go around in circles , but i believe my hypothesis to be correct until we have proof that it's false .

Hopefully, IMM will sign a major partnership deal in the near future to give them the necessary ressources to move forward promptly as nothing has progressed into clinical trials for many years.

Best regards